The Boston Beer Company (SAM) Q1 2025 Earnings Call April 25, 2025 05:36 AM ET Company Participants Michael Andrews - Associate General Counsel & Corporate SecretaryC. James Koch - Founder & ChairmanMichael Spillane - President & CEODiego Reynoso - CFO & TreasurerFilippo Falorni - Director - Equity ResearchEric Serotta - Executive DirectorBonnie Herzog - Managing Director Robert Ottenstein - Senior Managing Director & Partner Conference Call Participants Peter Grom - Equity Research AnalystNadine Sarwat - A ...

Digital Realty Trust (DLR) Q1 2025 Earnings Call April 25, 2025 03:41 AM ET Company Participants Jordan Sadler - SVP, Public & Private IRAndrew Power - President & CFOMatt Mercier - Chief Financial OfficerJonathan Atkin - Managing DirectorRichard Choe - Vice PresidentAri Klein - Director - Equity ResearchGreg Wright - Chief Investment OfficerMatthew Niknam - Director, Equity ResearchChris Sharp - Chief Technology OfficerAlexander Waters - Vice President, Equity Research - Communications InfrastructureMichae ...

Atlantic Union Bankshares (AUB) Q1 2025 Earnings Call April 25, 2025 02:59 AM ET Company Participants Bill Cimino - Senior Vice President, Investor RelationsJohn Asbury - President and CEORob Gorman - EVP & CFOCatherine Mealor - Managing Director - Equity ResearchDavid Bishop - DirectorDavid Ring - Executive VP & Wholesale Banking Group ExecutiveBrian Wilczynski - Vice President - Equity ResearchDoug Woolley - Chief Credit OfficerSteve Moss - Director Conference Call Participants Stephen Scouten - Managing ...

Skechers U.S.A. (SKX) Q1 2025 Earnings Call April 25, 2025 02:39 AM ET Company Participants Soo Hwang - Senior Director - International MerchandisingDavid Weinberg - Chief Operating OfficerJohn Vandemore - Chief Financial OfficerJay Sole - Managing DirectorPeter McGoldrick - Equity Research AssociateAlexandra Straton - Equity Research Managing DirectorJohn Kernan - Managing DirectorJesalyn Wong - DirectorJosh Reiss - Equity Research Senior AssociateChristopher Nardone - Director, Equity ResearchTom Nikic - ...

Merit Medical Systems (MMSI) Q1 2025 Earnings Call April 25, 2025 02:35 AM ET Company Participants Fred Lampropoulos - Founder, CEO & ChairmanBrian Lloyd - Chief Legal Officer and Corporate SecretaryRaul Parra - CFO & TreasurerSimran Modi - Vice PresidentMichael Petusky - Managing DirectorJon Young - DirectorJayson Bedford - Managing Director, Equity Research Conference Call Participants Jason Bednar - Senior Research AnalystSteve Lichtman - Managing Director, Senior Research AnalystRobbie Marcus - AnalystC ...

EastGroup Properties (EGP) Q1 2025 Earnings Call April 25, 2025 02:15 AM ET Company Participants Marshall Loeb - President & CEONone - ExecutiveBrent Wood - Executive VP, CFO & TreasurerSamir Khanal - DirectorAlexander Goldfarb - Managing DirectorJohn Kim - Managing Director - US Real EstateVikram Malhotra - Managing DirectorRonald Kamdem - Managing Director & Head of US REITs and CRE ResearchOmotayo Okusanya - Managing DirectorRichard Anderson - Managing Director - Equity ResearchMichael Carroll - Managing ...

Intel (INTC) Q1 2025 Earnings Call April 25, 2025 01:57 AM ET Company Participants Lip-Bu Tan - CEOJohn Pitzer - Corporate VP-IRDavid Zinsner - Interim Co-CEO, Executive VP & CFORoss Seymore - Managing DirectorTimothy Arcuri - Managing DirectorJoseph Moore - Managing DirectorMichelle Johnston Holthaus - Interim co-CEO and CEO of Intel ProductsCJ Muse - Senior Managing DirectorVijay Rakesh - Managing DirectorSrini Pajjuri - Managing DirectorThomas O'Malley - Director - Equity ResearchVivek Arya - Managing Di ...

SLM (SLM) Q1 2025 Earnings Call April 25, 2025 01:16 AM ET Company Participants Kate deLacy - Senior Director, Head of Investor RelationsJonathan Witter - CEO & DirectorPete Graham - EVP & CFOJeffrey Adelson - Executive DirectorNathaniel Richam-Odoi - Equity Research AssociateJohn Hecht - Managing DirectorMark Devries - Director Conference Call Participants Terry Ma - Senior Equity Research AnalystMoshe Orenbuch - Managing Director & Senior AnalystMichael Kaye - Equity Research AnalystRichard Shane - Stock ...

Financial Data and Key Metrics Changes - The base business, excluding Veclury, grew 4% year over year, primarily driven by growth in the HIV business [6][50] - Total product sales, including Veclury, were down by 1% from last year, reflecting fewer COVID-19 related hospitalizations [8][50] - Non-GAAP diluted EPS was $1.81, with a product gross margin flat year over year at 85% [52][54] Business Line Data and Key Metrics Changes - HIV sales were up 6% year over year, with Biktarvy sales increasing by 7% [7][22] - Livedelzi achieved first-quarter sales of $40 million, reflecting early momentum in its launch [27] - Veclury sales were down 45% year over year, reflecting lower rates of COVID-19 related hospitalizations [28] - Trodelvy sales were down 5% year over year, impacted by inventory dynamics and lower average realized price [29][98] - Cell therapy sales were down 3% year over year, with Yescarta sales up 2% year over year [31] Market Data and Key Metrics Changes - The HIV treatment market continues to grow at an expected rate of 23% annually [22] - Descovy sales increased by 38% year over year, driven by higher average realized price and demand [23][78] - The liver disease segment saw sales of $758 million, up 3% year over year [26] Company Strategy and Development Direction - The company is focused on multiple upcoming launches, including lenacapavir, anetocel, and Trodelvy [13][34] - Gilead Sciences, Inc. has no major loss of exclusivity (LOE) until the end of 2033, positioning itself for top-line growth across therapeutic areas [14] - The company is increasing investment in US manufacturing and R&D infrastructure [15][89] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming FDA decision on lenacapavir for PrEP, with a potential launch immediately following [9][38] - The company remains well-positioned to adapt to potential policy outcomes in the US [14] - Management noted that the first quarter was lighter than expected but emphasized the variability of the business [54][93] Other Important Information - Gilead Sciences, Inc. received an upgrade in its long-term debt rating from BBB+ to A- [58] - The company returned $1.7 billion to shareholders in the first quarter of 2025 through dividends and share repurchases [58] Q&A Session Summary Question: Expectations for lenacapavir for PrEP and reimbursement dynamics - Management is excited about the upcoming PDUFA date and expects around 75% access within the first six months post-launch, reaching about 90% at the twelve-month mark [62] Question: Impact of HHS and CDC cuts on launch dynamics - Management has not seen anything that would alter plans for the lenacapavir launch and is actively engaging with policymakers [68] Question: Implications of COVID-19 on Descovy and lenacapavir - Descovy saw a 38% growth year over year, driven by market development initiatives, which supports the opportunity for lenacapavir [78] Question: Tariff risks and US market supply - Management indicated that the majority of Gilead's IP is in the US, which suggests lower value for pharmaceutical imports, and they have invested significantly in US manufacturing [86][89] Question: Cannibalization of Descovy by lenacapavir - Management believes lenacapavir will attract both switch patients from daily orals and naive patients, potentially accelerating market growth [124]

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...